Direct comparison
GCP vs. GMP: What's the Difference?
GCP governs how clinical trials are conducted; GMP governs how the investigational product is manufactured. Compare scope, regulations, and oversight.
Side-by-side comparison
| Dimension | GCP | GMP |
|---|---|---|
| Full name | Good Clinical Practice | Good Manufacturing Practice |
| What it governs | Conduct of the clinical trial itself — informed consent, protocol adherence, investigator/sponsor responsibilities, data integrity | Manufacturing, testing, and release of the drug substance/product, including investigational product (IMP) used in trials |
| Core guideline / US regulation | ICH E6(R2)/(R3); implemented via 21 CFR Part 312, with informed-consent/IRB requirements in 21 CFR Parts 50 and 56 | 21 CFR Parts 210 and 211 (drug cGMP) |
| Key international framework | ICH E6, harmonized across ICH regions (FDA, EMA, PMDA and others) | ICH Q7 (GMP for active pharmaceutical ingredients); EU GMP Annex 13/16 for investigational medicinal products |
| Who is regulated | Clinical investigators, sponsors, CROs, monitors, institutional review boards (IRBs) | Manufacturing facilities and the parties responsible for producing, testing, and releasing the product |
| Unit of compliance | Per trial/per site — protocol adherence and data integrity assessed per subject and site | Per facility/quality system — ongoing compliance of the manufacturing site and process |
| Oversight role | IRB/IEC, sponsor’s clinical monitor, GCP auditors | Quality unit; in the EU, a Qualified Person (QP) who certifies batch release |
| Core focus | Human-subject protection and the integrity/reliability of trial data | Product identity, purity, potency, and consistency |
| Key documentation | Trial master file (TMF), case report forms (CRFs), informed consent forms | Batch records, standard operating procedures (SOPs), certificates of analysis |
| FDA inspection program | Bioresearch Monitoring (BIMO) Program — inspects investigators, sponsors/monitors/CROs, IRBs | Separate drug-manufacturing surveillance and pre-approval inspections — not covered by BIMO |
| Phase-based flexibility | None — core informed-consent, protocol-adherence, and monitoring expectations apply from first-in-human onward | Yes — 21 CFR 210.2(c) exempts most Phase 1 investigational drugs from the full scope of Part 211 |
| Relationship to GLP | Distinct — GLP (21 CFR Part 58) governs the nonclinical/preclinical safety studies that precede human dosing | Distinct — GLP governs preclinical studies; GMP governs manufacture of the product used later in trials |
Common questions
FAQ
Do I need GCP or GMP compliance for a clinical trial?+
Both, for different parts of the trial. GCP (ICH E6, 21 CFR Part 312) governs how the trial is conducted — informed consent, protocol adherence, data integrity. GMP (21 CFR Parts 210/211) governs how the investigational product administered in the trial was manufactured. A trial needs both a GCP-compliant conduct plan and a GMP-manufactured product.
Can a site be GCP-compliant if the investigational product wasn’t manufactured under GMP?+
No — they are separate but both required. A site can run flawless GCP-compliant trial conduct while the product itself was manufactured out of GMP compliance, and that is still a serious regulatory problem for the sponsor. The two compliance regimes are assessed and enforced independently.
Who inspects GCP vs. GMP?+
FDA’s Bioresearch Monitoring (BIMO) Program inspects GCP compliance at clinical investigator sites, sponsors/monitors/CROs, and IRBs. GMP compliance at manufacturing facilities is inspected separately, through drug-manufacturing surveillance and pre-approval inspections that are not part of BIMO.
Is GCP the same as GLP?+
No. GCP governs the human clinical trial itself. GLP (21 CFR Part 58) governs the nonclinical/preclinical safety and toxicology studies conducted before human dosing begins. See GLP vs. GMP for how GLP compares to manufacturing quality.
Does GMP apply differently in early-phase trials?+
Yes. Under 21 CFR 210.2(c), most Phase 1 investigational drugs are exempt from the full scope of 21 CFR Part 211, with manufacturing controls expected to increase through later trial phases. GCP has no equivalent phase-based exemption — core conduct expectations apply from first-in-human trials onward.
Going deeper
